About Implantica
Implantica is a publicly listed company based in Zug (Switzerland) founded in 2003 by Peter Forsell. It develops implantable devices for medical conditions such as acid reflux and urology. It operates on a B2B model. Its chief executive is Peter Forsell. Implantica offers products and services including RefluxStopâ„¢ and e-InVivoâ„¢. Its focus areas include Technology, eHealth, Implantable Platforms and Wireless Energizing. Its legal entity is Implantica AG. Its competitors include Endotronix, Edwards Lifesciences, CoachCare, BioIntelliSense and Oxehealth and 5 more; 9 of its 10 listed competitors have raised funding.
Company details
Implantica specializes in creating advanced smart medical implants to address unmet healthcare needs, including acid reflux treatment and eHealth platforms. The company patents wireless energizing technologies and focuses on areas like urology and gastrointestinal issues. Based in Vaduz, Liechtenstein, and Zug, Switzerland, they collaborate with professionals and aim to revolutionize healthcare through innovative, non-commercially available solutions.
- Headquarters Zug, Switzerland
- Founders Peter Forsell
- Stage Public
- SectorsHealthcare
- Phone•••• ••••
- Website implantica.com
- Social LinkedIn
- Legal Name Implantica Inc. Shs A Swedish Depositary Receipt Repr 1 Sh A
- Annual Revenue$2.49 M (USD)3.63as on Dec 31, 2025
- Net Profit-$23.59 M (USD)18.59as on Dec 31, 2025
- EBITDA-$21.31 M (USD)22.57as on Dec 31, 2025
Products & Services of Implantica
Implantica offers a comprehensive portfolio of products and services, including RefluxStop™ and e-InVivo™.
Device that treats acid reflux causes in patients.
Implantable system for advanced healthcare monitoring.
People of Implantica
23 people are tracked at Implantica (11 in leadership, 4 in board & advisors, 8 in team).
| Name | Role | Group |
|---|---|---|
Peter Forsell | CEO, Founder | Leadership |
Andreas Öhrnberg | CFO | Leadership |
Stephan Siegenthaler | Chief Strategy Officer | Leadership |
Leif Granat | VP, R&D | Leadership |
Amit Kukreja | Chief Market Access & Strategy Officer | Leadership |
Nicole Pehrsson | Chief Corporate Affairs Officer | Leadership |
Juliette Cook | VP, Quality & Regulatory Affairs | Leadership |
Christophe Aubert | R&d VP Mechanical Development | Leadership |
Juanita Eberhart | Vice President Marketing | Leadership |
Melanie Houselog | Sr. Director And Head Of Global Quality & Regulatory Affairs | Leadership |
Chris Rossmith | Vice President Of Ehealth | Leadership |
Tomas Puusepp | Director | Board & advisors |
Johan Bojs | Vice-Chairman of The Board | Board & advisors |
Klaus Neftel | Director | Board & advisors |
Liselott Kilaas | Chairman of the Board | Board & advisors |
Andrew Galea | Business Controller | Team |
Bianca Torres | Digital Marketing Manager | Team |
Vanessa Kemp | Senior Congress & Event Manager | Team |
Erika Ismailova | Staff PMS & QA Specialist | Team |
Mason Friedman | Senior Graphic Designer | Team |
3 more people are available in the full profile.
Complete people profiles for Implantica
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of Implantica
Implantica is a publicly listed company on the OMXSTO with ticker symbol IMP_A_SDB in Sweden, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date21 Sep 2020
- Listed onOMXSTO: IMP_A_SDB
- Listed entityImplantica Inc. Shs A Swedish Depositary Receipt Repr 1 Sh A
- Exchange sectorHealth technology
- ISINSE0014855029
- Share price62.90 SEK (+0.48% on the day) · 2026-10-14
- Market capitalisation4,358,819,114.00 SEK
- EPS (diluted, trailing year)-3.10 SEK
- Volume (last session)17,154
Financials of Implantica
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2025 | 22.9M SEK | -217.2M SEK | -196.3M SEK |
| 2024 | 22.1M SEK | -266.9M SEK | -253.5M SEK |
| 2023 | 16.2M SEK | -272.5M SEK | -232.4M SEK |
| 2022 | 9.0M SEK | -221.5M SEK | -178.2M SEK |
| 2021 | 3.9M SEK | -155.9M SEK | -119.0M SEK |
Detailed financial statements for Implantica
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Competitors of Implantica
Implantica has 10 listed competitors in our database, 9 of them funded. They include Endotronix, Edwards Lifesciences, CoachCare, BioIntelliSense and Oxehealth, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| endotronix.com | 2007 | East Peoria, United States | $154.77M | 104 | Miniaturized wireless implantable sensors are developed for hemodynamic monitoring. | |
| edwards.com | 1958 | Irvine, United States | – | 19,800 | Medical devices for structural heart disease are developed and provided. | |
| coachcare.com | 2013 | New York, United States | $60.2M | – | Remote monitoring platform for tracking patient activity | |
| biointellisense.com | 2018 | Redwood, United States | $82M | 26 | Vital signs are monitored via a single-use patch and platform. | |
| oxehealth.com | 2012 | Leeds, United Kingdom | $7.14M | 95 | Contactless patient monitoring is provided for mental health facilities. | |
| openwater.health | 2016 | San Francisco, United States | $54M | – | Provider of imaging technologies for medical diagnosis and treatments | |
| endogastricsolutions.com | 2002 | San Mateo, United States | $355.2M | 80 | Incisionless transoral procedures for upper GI diseases are developed. | |
| somatix.com | 2015 | New York, United States | $21.24M | – | AI-based remote health monitoring tools are provided for patient care. | |
| higi.com | 2012 | Chicago, United States | $95.23M | 53 | Gamified app for personal health management | |
| endochoice.com | 2008 | Alpharetta, United States | $115.96M | 414 | Devices, systems, and services are provided for GI specialists. |
Detailed competitors of Implantica
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Implantica
The website of Implantica (implantica.com) receives about 2.4K visits a month.
- Monthly visits2.4K
▲ 91.6% vs previous month
Top companies in Health Monitoring & Wearables
10 companies that operate in the same segment as Implantica (Health Monitoring & Wearables), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Smart fitness equipment and streaming platforms are provided. | 2011 | New York, New York, United States | USD 995.53 M | USD 2.45 B | 2,894 | |
Connected devices for health, sleep, and activity monitoring are developed. | 2008 | Moulineaux, Seine-maritime, France | USD 93.83 M | – | – | |
Internet first brand offering wearable breast pumps | 2013 | London, England, United Kingdom | USD 157.63 M | – | – | |
Metabolic health is tracked via devices and fitness platforms. | 2019 | Bengaluru, Karnataka, India | USD 163.28 M | USD 65.48 M | 274 | |
Health-tracking smart rings and biosensors are developed for biometric monitoring. | 2013 | Oulu, North Ostrobothnia, Finland | USD 1.32 B | USD 398.5 M | 1,632 | |
Wearable glucose monitoring patches are provided for real-time data tracking. | 1999 | San Diego, California, United States | USD 52.5 M | USD 4.66 B | 10,300 | |
AI-based mobile app tracks and predicts menstrual cycles. | 2015 | London, England, United Kingdom | USD 269 M | USD 275.25 M | 701 | |
Smartphone-enabled glucometers and diabetes management apps are provided. | 2015 | Delhi, Delhi, India | USD 50.83 M | USD 2.74 M | 142 | |
Provider of a fertility tracking app that doubles as birth control | 2013 | Stockholm, Sweden | USD 99.5 M | – | – | |
Diabetes management is enabled via glucose meters and mobile apps. | 2010 | Palo Alto, California, United States | USD 201 M | – | – |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Implantica
Complete news archive for Implantica
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Implantica
Implantica was founded in 2003.
Implantica is headquartered in Zug, Switzerland. It is registered at Zug, Zug, Switzerland.
Peter Forsell is the current CEO of Implantica. They have also founded this company.
Annual revenue of Implantica is $2.49M as on Dec 31, 2025.
Implantica specializes in creating advanced smart medical implants to address unmet healthcare needs, including acid reflux treatment and eHealth platforms. The company patents wireless energizing technologies and focuses on areas like urology and gastrointestinal issues. Based in Vaduz, Liechtenstein, and Zug, Switzerland, they collaborate with professionals and aim to revolutionize healthcare through innovative, non-commercially available solutions.
Implantica's top competitors include Endotronix, Oxehealth and BioIntelliSense.
Implantica offers RefluxStopâ„¢ and e-InVivoâ„¢.
Yes, Implantica is publicly traded on OMXSTO under the ticker symbol IMP_A_SDB.
Implantica operates through Implantica Ag.